Chen YP, Yin JH, Li WF, Li HJ, Chen DP, Zhang CJ, Lv JW, Wang YQ, Li XM, Li JY, et al. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res. 2020;30:1024–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsao SW, Tsang CM, To KF, Lo KW. The role of Epstein-Barr virus in epithelial malignancies. J Pathol. 2015;235:323–33.

Article  CAS  PubMed  Google Scholar 

Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med. 1995;333:693–8.

Article  CAS  PubMed  Google Scholar 

Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci 2017, 372.

Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503–10.

Article  CAS  PubMed  Google Scholar 

Dawson CW, Port RJ, Young LS. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol. 2012;22:144–53.

Article  CAS  PubMed  Google Scholar 

Elgui de Oliveira D, Müller-Coan BG, Pagano JS. Viral carcinogenesis beyond Malignant Transformation: EBV in the progression of human cancers. Trends Microbiol. 2016;24:649–64.

Article  CAS  PubMed  Google Scholar 

Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, Hong RL, Whang-Peng J, Ma BB, To KF, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 2005;23:3568–76.

Article  CAS  PubMed  Google Scholar 

Ma BBY, Kam MKM, Leung SF, Hui EP, King AD, Chan SL, Mo F, Loong H, Yu BKH, Ahuja A, Chan ATC. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2012;23:1287–92.

Article  CAS  PubMed  Google Scholar 

Shen J, Sun C, Zhou M, Zhang Z. Combination treatment with cetuximab in advanced nasopharyngeal carcinoma patients: a meta-analysis. Onco Targets Ther. 2019;12:2477–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 2004;25:158–64.

Article  CAS  PubMed  Google Scholar 

Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood. 2008;111:1456–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wåhlin B, Perlmann H, Perlmann P, Schreiber RD, Müller-Eberhard HJ. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments. J Immunol. 1983;130:2831–6.

Article  PubMed  Google Scholar 

Hsu YF, Ajona D, Corrales L, Lopez-Picazo JM, Gurpide A, Montuenga LM, Pio R. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. Mol Cancer. 2010;9:139.

Article  PubMed  PubMed Central  Google Scholar 

Kang X, Patel D, Ng S, Melchior M, Ludwig D, Hicklin D, Show J. High affinity fc receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab. J Clin Oncol 2007, 25.

Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol. 2003;40:109–23.

Article  CAS  PubMed  Google Scholar 

He Y, Lin F, Chipman PR, Bator CM, Baker TS, Shoham M, Kuhn RJ, Medof ME, Rossmann MG. Structure of decay-accelerating factor bound to echovirus 7: a virus-receptor complex. Proc Natl Acad Sci U S A. 2002;99:10325–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geller A, Yan J. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy. Front Immunol. 2019;10:1074.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen Y, Yin R, Deng X, Shen H. Increased expression of CD55 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Clin Invest Med. 2012;35:E34–39.

Article  CAS  PubMed  Google Scholar 

Madjd Z, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE. Loss of CD55 is associated with aggressive breast tumors. Clin Cancer Res. 2004;10:2797–803.

Article  CAS  PubMed  Google Scholar 

Mustafa T, Klonisch T, Hombach-Klonisch S, Kehlen A, Schmutzler C, Koehrle J, Gimm O, Dralle H, Hoang-Vu C. Expression of CD97 and CD55 in human medullary thyroid carcinomas. Int J Oncol. 2004;24:285–94.

CAS  PubMed  Google Scholar 

Xiang T, Lin YX, Ma W, Zhang HJ, Chen KM, He GP, Zhang X, Xu M, Feng QS, Chen MY, et al. Vasculogenic mimicry formation in EBV-associated epithelial malignancies. Nat Commun. 2018;9:5009.

Article  PubMed  PubMed Central  Google Scholar 

Duan X, Chen H, Zhou X, Liu P, Zhang X, Zhu Q, Zhong L, Zhang W, Zhang S, Zhang X, et al. EBV Infection in epithelial malignancies induces resistance to Antitumor Natural Killer cells via F3-Mediated platelet aggregation. Cancer Res. 2022;82:1070–83.

Article  CAS  PubMed  Google Scholar 

Chen H, Duan X, Deng X, Huang Y, Zhou X, Zhang S, Zhang X, Liu P, Yang C, Liu G, et al. EBV-Upregulated B7-H3 inhibits NK cell-mediated antitumor function and contributes to nasopharyngeal carcinoma progression. Cancer Immunol Res. 2023;11:830–46.

Article  CAS  PubMed  Google Scholar 

Ouyang Q, Zhang L, Jiang Y, Ni X, Chen S, Ye F, Du Y, Huang L, Ding P, Wang N, et al. The membrane complement regulatory protein CD59 promotes tumor growth and predicts poor prognosis in breast cancer. Int J Oncol. 2016;48:2015–24.

Article  CAS  PubMed  Google Scholar 

Li B, Lin H, Fan J, Lan J, Zhong Y, Yang Y, Li H, Wang Z. CD59 is overexpressed in human lung cancer and regulates apoptosis of human lung cancer cells. Int J Oncol. 2013;43:850–8.

Article  CAS  PubMed  Google Scholar 

You R, Liu YP, Lin DC, Li Q, Yu T, Zou X, Lin M, Zhang XL, He GP, Yang Q, et al. Clonal mutations activate the NF-kappaB pathway to promote recurrence of nasopharyngeal carcinoma. Cancer Res. 2019;79:5930–43.

Article  CAS  PubMed  Google Scholar 

Cheung ST, Huang DP, Hui ABY, Lo KW, Ko CW, Tsang YS, Wong N, Whitney BM, Lee JCK. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer. 1999;83:121–6.

Article  CAS  PubMed  Google Scholar 

Wang LW, Jiang S, Gewurz BE. Epstein-Barr Virus LMP1-Mediated oncogenicity. J Virol 2017, 91.

Lo AK, Dawson CW, Lung HL, Wong KL, Young LS. The role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: from function to Therapy. Front Oncol. 2021;11:640207.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lo AK, To KF, Lo KW, Lung RW, Hui JW, Liao G, Hayward SD. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci U S A. 2007;104:16164–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen YM, Yin RX, Deng XG, Shen H. Increased expression of CD55 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Clin Invest Med. 2012;35:E34–9.